Hinova Pharmaceuticals Inc
SSE:688302
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
iClick Interactive Asia Group Ltd
NASDAQ:ICLK
|
HK |
Hinova Pharmaceuticals Inc
Capital Expenditures
Hinova Pharmaceuticals Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hinova Pharmaceuticals Inc
SSE:688302
|
Capital Expenditures
-¥89.5m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-140%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Capital Expenditures
-¥293.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Capital Expenditures
-¥3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Capital Expenditures
-¥479.7m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-13%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Capital Expenditures
-¥1.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Capital Expenditures
-¥83.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Hinova Pharmaceuticals Inc
Glance View
Hinova Pharmaceuticals, Inc. engages in the research and development of pharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 160 full-time employees. The company went IPO on 2022-04-12. The firm focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The firm's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The firm has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The firm conducts clinical tests in domestic and overseas areas.
See Also
What is Hinova Pharmaceuticals Inc's Capital Expenditures?
Capital Expenditures
-89.5m
CNY
Based on the financial report for Dec 31, 2024, Hinova Pharmaceuticals Inc's Capital Expenditures amounts to -89.5m CNY.
What is Hinova Pharmaceuticals Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-140%
Over the last year, the Capital Expenditures growth was 10%. The average annual Capital Expenditures growth rates for Hinova Pharmaceuticals Inc have been -65% over the past three years , -140% over the past five years .
